These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 28095307)

  • 41. [HIV pre-exposure prophylaxis (PreP): The three should not prevent seing the forest].
    Casabona J
    Aten Primaria; 2017; 49(6):317-318. PubMed ID: 28521860
    [No Abstract]   [Full Text] [Related]  

  • 42. Sexually transmitted infections in the era of antiretroviral-based HIV prevention: Priorities for discovery research, implementation science, and community involvement.
    Marrazzo JM; Dombrowski JC; Mayer KH
    PLoS Med; 2018 Jan; 15(1):e1002485. PubMed ID: 29320494
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Letter to the editor: Pre-exposure prophylaxis for HIV in Europe: The need for resistance surveillance.
    van Tienen C; van de Vijver D; Noori T; Sönnerborg A; Boucher C
    Euro Surveill; 2017 Mar; 22(11):. PubMed ID: 28333614
    [No Abstract]   [Full Text] [Related]  

  • 44. Silver bullets and structural impediments to HIV prevention.
    Mayer KH; Sullivan PS; Beyrer C
    Lancet HIV; 2019 Nov; 6(11):e729-e732. PubMed ID: 31451415
    [No Abstract]   [Full Text] [Related]  

  • 45. Postexposure prophylaxis for HIV: pivotal intervention for those at risk.
    Sharifi-Azad J; Rizzolo D
    JAAPA; 2011 Aug; 24(8):22-5. PubMed ID: 21850915
    [No Abstract]   [Full Text] [Related]  

  • 46. [Pre-exposure antiretroviral prophylaxis for human immunodeficiency virus (HIV) infection].
    Castilla J
    Semergen; 2020 Apr; 46(3):151-152. PubMed ID: 32234283
    [No Abstract]   [Full Text] [Related]  

  • 47. PrEP for HIV: grade A for evidence but pending for impact.
    Baeten JM
    Nat Rev Urol; 2019 Oct; 16(10):570-571. PubMed ID: 31363183
    [No Abstract]   [Full Text] [Related]  

  • 48. [Program of Pre-exposure Prophylaxis against HIV (PreP) of the Ministry of Health in Chile].
    Zapata Pizarro A; Muena Bugueño C; Quiroz Nilo S; Valenzuela Cruz J
    Rev Med Chil; 2020 Dec; 148(12):1860. PubMed ID: 33844756
    [No Abstract]   [Full Text] [Related]  

  • 49. Once-a-year implant shows promise against HIV.
    Cohen J
    Science; 2019 Jul; 365(6451):309. PubMed ID: 31346047
    [No Abstract]   [Full Text] [Related]  

  • 50. Remarks on the article of Hadas et al.: Transmission of chimeric HIV by mating in conventional mice: prevention by pre-exposure antiretroviral therapy and reduced susceptibility during estrus.
    Anderson DJ; Politch JA
    Dis Model Mech; 2014 Feb; 7(2):177-8. PubMed ID: 24713273
    [No Abstract]   [Full Text] [Related]  

  • 51. Response to 'Remarks on the article of Hadas et al.: Transmission of chimeric HIV by mating in conventional mice: prevention by pre-exposure antiretroviral therapy and reduced susceptibility during estrus'.
    Potash MJ; Hadas E; Volsky DJ
    Dis Model Mech; 2014 Feb; 7(2):178-9. PubMed ID: 24713274
    [No Abstract]   [Full Text] [Related]  

  • 52. HIV infection in the setting of PrEP: Development of antiretroviral resistance and breakthrough infection. Report of two cases in real-life.
    Chivite I; Riera-Monroig J; Ambrosioni J; Laguno M
    Enferm Infecc Microbiol Clin (Engl Ed); 2022 May; 40(5):280-281. PubMed ID: 35577448
    [No Abstract]   [Full Text] [Related]  

  • 53. Expectations and acceptability of long-acting injectable antiretrovirals by patients living with HIV/AIDS.
    Palacios C; Wilpotte C; Adda A; Allaf S; Thibaut P; Chas J; Siguier M; Pialoux G
    Infect Dis Now; 2022 Jun; 52(4):238-239. PubMed ID: 35172216
    [No Abstract]   [Full Text] [Related]  

  • 54. Implementing HIV PrEP in Routine Practice.
    Sell J
    Am Fam Physician; 2023 Sep; 108(3):227-228. PubMed ID: 37725449
    [No Abstract]   [Full Text] [Related]  

  • 55. Electronic health record tools to catalyse PrEP conversations.
    Ortblad KF; Baeten JM
    Lancet HIV; 2019 Oct; 6(10):e644-e645. PubMed ID: 31285180
    [No Abstract]   [Full Text] [Related]  

  • 56. Vaginal dysbiosis and pre-exposure prophylaxis efficacy.
    van de Wijgert J; McCormack S
    Lancet HIV; 2017 Oct; 4(10):e427-e429. PubMed ID: 28732774
    [No Abstract]   [Full Text] [Related]  

  • 57. The Pathways and Resources for Participation and Engagement (PREP): methodological contributions to environment-focused interventions.
    Kramer JM
    Dev Med Child Neurol; 2018 May; 60(5):442-443. PubMed ID: 29517111
    [No Abstract]   [Full Text] [Related]  

  • 58. A Patient's Perspective on Privilege as a Prerequisite for PrEP.
    Hanshaw BD; Rosengren AL
    J Assoc Nurses AIDS Care; 2021 Jul-Aug 01; 32(4):418-422. PubMed ID: 33883528
    [No Abstract]   [Full Text] [Related]  

  • 59. The effect of oral preexposure prophylaxis on the progression of HIV-1 seroconversion.
    Donnell D; Ramos E; Celum C; Baeten J; Dragavon J; Tappero J; Lingappa JR; Ronald A; Fife K; Coombs RW;
    AIDS; 2017 Sep; 31(14):2007-2016. PubMed ID: 28692542
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Evaluation of a Multidrug Assay for Monitoring Adherence to a Regimen for HIV Preexposure Prophylaxis in a Clinical Study, HIV Prevention Trials Network 073.
    Zhang Y; Clarke W; Marzinke MA; Piwowar-Manning E; Beauchamp G; Breaud A; Hendrix CW; Cloherty GA; Emel L; Rose S; Hightow-Weidman L; Siegel M; Shoptaw S; Fields SD; Wheeler D; Eshleman SH
    Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28438932
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.